Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

Conditions

• Deleterious BRCA1 Gene Mutation
• Deleterious BRCA2 Gene Mutation
• Loss of Heterozygosity
• Lung Non-Small Cell Squamous Carcinoma
• Recurrent Large Cell Lung Carcinoma
• Recurrent Lung Adenocarcinoma
• Recurrent Lung Non-Small Cell Carcinoma
• Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
• Stage IV Lung Cancer AJCC v8
• Stage IVA Lung Cancer AJCC v8
• Stage IVB Lung Cancer AJCC v8

Eligibility Criteria

Sex

ALL

Age

N/A - N/A

Healthy Volunteers

Not accepted

Interventions

• Rucaparib — DRUG
  Given PO

Study Details

This phase II Lung-MAP trial studies how well rucaparib works in treating patients with genomic loss of heterozygosity (LOH) high and/or deleterious BRCA1/2 mutation stage IV non-small cell lung cancer or that has come back. Rucaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Key Dates

Start date

Apr 16, 2019

Status verified

May 2025

Primary completion

Jan 1, 2022

Completion

Sep 21, 2024

Study Design

Enrollment

64 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (rucaparib)
  Patients receive rucaparib PO BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Primary Outcome Measure

Overall Response Rate [ Time Frame: From date of registration to a maximum of 3 years or death ]

Locations (950)

Find similar trials in Mobile, AL

Related Studies

• Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas
• Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
  PHASE2 · Recruiting · National Cancer Institute (NCI) · Anchorage, Alaska
• Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery
  PHASE1/PHASE2 · Recruiting · Stanford University · Palo Alto, California
• Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
  PHASE1 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas